9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.

>more

Learn about the role of HPV in cervical cancer
 
What's New

26. May 2015

Roche receives FDA clearance for the cobas® Cdiff Test to detect Clostridium difficile

New test expands menu for healthcare associated infections testing on the widely adopted cobas® 4800 System.

>more

19. May 2015

Roche Receives FDA CLIA Waiver for the cobas Liat PCR System and Strep A assay

cobas Strep A, the first molecular PCR test to deliver laboratory quality results in ~15 minutes, now available for use in physician offices and pharmacies.

>more

11. May 2015

Roche receives FDA approval for cobas® KRAS Mutation Test

Molecular PCR test identifies KRAS mutations to aid in determining therapy for metastatic colorectal cancer.

>more

19. March 2015

Roche announces global distribution agreement for its Biochemical Reagents product portfolio with Sigma-Aldrich

Roche announced today a global distribution agreement for its Biochemical Reagents product portfolio with Sigma-Aldrich Corporation. Sigma-Aldrich’s supply chain and eCommerce strength will allow broader availability and accessibility of products to customers.

>more

 Diagnostic and Blood Screening Tests

 

Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.

 

RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more

 Contact

Contact your local sales representative for detailed information, questions and ordering.

 

 

 Browse Our Products

 Related Links